Sunil Agarwal - Sep 15, 2021 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Role: EVP, Head of Development & CMO
Signature: /s/ James J. MacDonald, Attorney-in-Fact for Sunil Agarwal
Stock symbol: SANA
Transactions as of: Sep 15, 2021
Transactions value $: -$1,564,057
Form type: 4
Date filed: 9/17/2021, 04:27 PM
Previous filing: Jun 14, 2021
Next filing: Mar 8, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SANA	Common Stock	Sale	-$1.52M	-58.4K	-3.63%	$26.07	1.55M	Sep 15, 2021	Direct	F1, F2
transaction	SANA	Common Stock	Sale	-$42.3K	-1.63K	-0.1%	$26.00	1.55M	Sep 16, 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 5, 2021.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.225, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Content

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 5, 2021.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.225, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.